The 2017 Lasker Awards

doi:10.3969/j.issn.1006-7795.2017.05.028

Abstract

Abstract: In September 6, 2017, the list of winners of the year's Lasker Awards were released. The Albert Lasker Basic Medical Research Award honors Michael N. Hall from University of Basel, Switzerland, for his discovery of the nutrient-activated target of rapamycin (TOR) proteins and their central role in the metabolic control of cell growth. The Lasker~DeBakey Clinical Medical Research Award honors Douglas R. Lowy and John T. Schiller from the National Cancer Institute, whose technological advances enabled the development of human papillomavirus (HPV) vaccines, which prevent cervical cancer and other tumors. The 2017 Lasker~Bloomberg Public Service Award honors Planned Parenthood for providing essential health services and reproductive care to millions of women for more than a century.

Key words: Lasker Awards, TOR protein, human papillomavirus (HPV) vaccines, reproductive care

Wu Jianhong, Lu Dan, Zhang Ting, Dai Yinmei, Wang Xiaomin. The 2017 Lasker Awards[J]. Journal of Capital Medical University, 2017, 38(5): 777-781.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.05.028

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I5/777

References

[1] Evelyn Strauss. The 2017 LASKER AWARDS[EB/OL]. (2017-09-06). http://www.laskerfoundation.org/.
[2] Laplante M, Sabatini D M. mTOR signaling in growth control and disease[J]. Cell, 2012, 149(2):274-293.
[3] Liko D, Hall M N. mTOR in health and in sickness[J]. J Mol Med (Berl), 2015, 93(10):1061-1073.
[4] Heitman J, Movva N R, Hall M N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast[J]. Science, 1991, 253(5022):905-909.
[5] Kunz J, Henriquez R, Schneider U, et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression[J]. Cell, 1993, 73(3):585-596.
[6] Barbet N C, Schneider U, Helliwell S B, et al. TOR controls translation initiation and early G1 progression in yeast[J]. Mol Biol Cell, 1996, 7(1):25-42.
[7] Beck T, Hall M N. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors[J].Nature, 1999, 402(6762):689-692.
[8] Hall M N. TOR and paradigm change:cell growth is controlled[J]. Mol Biol Cell, 2016, 27(18):2804-2806.
[9] Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control[J]. Mol Cell, 2002, 10(3):457-468.
[10] Gonzalez A, Hall M N. Nutrient sensing and TOR signaling in yeast and mammals[J]. EMBO J, 2017, 36(4):397-408.
[11] Vaccarella S, Laversanne M, Ferlay J, et al. Cervical cancer in africa, latin America and the caribbean and asia:regional inequalities and changing trends[J]. Int J Cancer, 2017, 141(10):1997-2001.
[12] Ciesielska U, Nowińska K, Podhorska-Okołów M, et al. The role of human papillomavirus in the malignant transformation of cervix epithelial cells and the importance of vaccination against this virus[J]. Adv Clin Exp Med, 2012, 21(2):235-244.
[13] Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic[J]. Proc Natl Acad Sci U S A, 1992, 89(24):12180-12184.
[14] Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles[J]. J Virol, 1993, 67(12):6929-6936.
[15] Roden R B, Hubbert N L, Kirnbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition[J]. J Virol, 1996, 70(5):3298-3301.
[16] Harro C D, Pang Y Y, Roden R B, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine[J]. J Natl Cancer Inst, 2001, 93(4):284-292.
[17] Wu T, Hu Y M, Li J, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus(type 16 and 18) vaccine:A randomized controlled phase 2 clinical trial[J]. Vaccine, 2015, 33(32):3940-3946.
[18] Vesikari T, Brodszki N, van Damme P, et al. A randomized, rouble-blind, phase Ⅲ study of the immunogenicity and Safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil^® in 9-15-Year-Old Girls[J]. Pediatr Infect Dis J, 2015, 34(9):992-998.
[19] De Vincenzo R,Conte C,Ricci C,et al. Long-term efficacy and safety of human papillomavirus vaccination[J]. Int J Womens Health, 2014, 102(6):999-1010.
[20] Crawford N W,Hodgson K, Gold M, et al. Adverse events following HPV immunization in australia:establishment of a clinical network[J]. Hum Vaccin Immunother, 2016, 12(10):2662-2665.
[21] Petrosky E, Bocchini J A Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine:updated HPV vaccination recommendations of the advisory committee on immunization practices[J]. MMWR Morb Mortal Wkly Rep, 2015, 64(11):300-304.)